Glutamine-high z element compounds for treating cancer

Abstract

The present invention is a glutamine compound having a non-radioisotope high Z element attached via a linker, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.

Description

[0001]This application is a by-pass, continuation-in-part application of PCT / US16 / 52603, filed on Sep. 20, 2016, which designated the U.S. This application claims priority to PCT / US16 / 52603 filed on Sep. 20, 2016, which claims priority to U.S. provisional application 62 / 221,448, filed on Sep. 21, 2015.FIELD OF THE INVENTION[0002]The present invention describes a method for the ablation of targeted tissue or cells via the administration of non-radioisotope glutamine-high Z element compounds and subsequently exposing such tissue or cells to high energy radiation, including, but not limited to, x-rays, gamma rays, microwaves, alpha particles, protons, and neutrons. More specifically, the present invention describes a method for targeting the mitochondria of the aforementioned tissue or cells for destruction, thereby starving such cells of the energy they require to proliferate.BACKGROUND[0003]Radiation therapy is usually defined as the use of high-energy radiation from x-rays, gamma ra...

AI Technical Summary

Benefits of technology

The present invention provides compounds that can be used to enhance the effectiveness of radiation therapy. These compounds, when exposed to high-energy radiation, can destroy the structures of cancerous cells and deny them the energy and substrates they need for proliferation. This is helpful in fighting cancer.

Problems solved by technology

Radiation therapy, however, has its limitations.

The ionizing radiation used to ablate unwanted tissue can cause damage to surrounding healthy tissue, or may not be effective against the target tissue due to conditions such as hypoxia which makes the targeted cells radioresistent or cells being in a part of the mitotic cycle where they are not as sensitive to the effects of such radiation.

This substitution weakens the DNA chain and makes cells more susceptible to radiation and ultraviolet light.

It has also been theorized that the drug cisplatin, a chemotherapeutic drug that is known to have radiosensitizing properties, may cause damage to mitochondrial structures.

However, under such hypoxic conditions, the resulting pyruvate is not transported into the mitochondria for further processing, but rather remains in the cytoplasm where it is converted to lactate by lactic acid fermentation and expelled from the cell.

Interestingly, it has been observed for some time that even in the presence of oxygen, rapidly proliferating tumorigenic cells have a preference for inefficient anaerobic respiration and therefore utilize an abnormally high amount of glucose.

However, their usefulness as therapies for humans has been limited due to their high toxicity.

To date, there has been no drug specifically designed as a radiosensitizer that targets the mitochondria of tumorigenic tissue and cells for destruction.

Images